Xuezhi Yang

Xuezhi Yang

Auto-generated profile, based on publicly available information

Xuezhi Yang

Institute of Clinical Pharmacology, School of Pharmacy; Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Anhui Medical University, Hefei 230032, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Cell Proliferation
Verified
Journal Article
Open access
PDF file
XYXuezhi Yang
Xuezhi Yang
YCYan Chang
Yan Chang
WWWei Wei
Wei Wei
Macrophages maintain a dynamic balance in physiology. Various known or unknown microenvironmental signals influence the polarization, activation and death of macrophages, which creates an imbalance that leads to disease. Rheumatoid arthritis (RA) is characterized by the massive infiltration of a variety of chronic inflammatory cells in synovia. Abundant activated macrophages found in RA synovia are an early hallmark of RA, and the number of these macrophages can be decreased after effective treatment. In RA, the proportion of M1 (pro‐inflammatory macrophages) is higher than that of M2 (anti‐inflammatory macrophages). The increased pro‐inflammatory ability of macrophages is related to their excessive activation and proliferation as well as an enhanced anti‐apoptosis ability. At present, there are no clinical therapies specific to macrophages in RA. Understanding the mechanisms and functional consequences of the heterogeneity of macrophages will aid in confirming their potential role in inflammation development. This review will outline RA‐related macrophage properties (focus on polarization, metabolism and apoptosis) as well as the origin of macrophages. The molecular mechanisms that drive macrophage properties also be elucidated to identify novel therapeutic targets for RA and other autoimmune disease.

1 February 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
YZYingjie Zhao
Yingjie Zhao
XSXiaojing Sun
Xiaojing Sun
XYXuezhi Yang
Xuezhi Yang
BZBingjie Zhang
Bingjie Zhang
SLSiyu Li
Siyu Li
WWWei Wei
Wei Wei
Tolerogenic dendritic cells (tolDCs) have received much attention because of their capacity to restore immune homeostasis. RNA interference techniques have been used in several studies to generate tolDCs by inactivating certain molecules that regulate DC maturation and immunologic function. BAFF is a key B cell survival factor that is not only essential for B cell function but also T cell costimulation, and DCs are the major source of BAFF. In this study, we determined whether BAFF gene silencing in mature DCs could lead to a tolerogenic phenotype as well as the potential therapeutic effect of BAFF-silenced DCs on collagen-induced arthritis (CIA) in mice. Meanwhile, CRISPR/Cas9-mediated BAFF−/− DC2.4 cells were generated to verify the role of BAFF in DC maturation and functionality. BAFF-silenced DCs and BAFF−/− DC2.4 cells exhibited an immature phenotype and functional state. Further, the transplantation of BAFF-silenced DCs significantly alleviated CIA severity in mice, which correlated with a reduction in Th17 populations and increased regulatory T cells. In vitro, BAFF-silenced DCs promoted Foxp3 mRNA and IL-10 expression but inhibited ROR-γt mRNA and IL-17A expression in CD4+ T cells. Together, BAFF-silenced DCs can alleviate CIA, partly by inducing Foxp3+ regulatory T cells and suppressing Th17 subsets. Collectively, BAFF plays an important role in interactions between DCs and T cells, which might be a promising genetic target to generate tolDCs for autoimmune arthritis treatment. Key Points BAFF-silenced DCs exhibited an immature and tolerogenic phenotype. BAFF-silenced DCs alleviated mouse CIA by modulating the Th17/Treg balance. BAFF might be a promising genetic target to generate tolDCs for RA treatment.

12 August 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
WZWankang Zhang
Wankang Zhang
LWLuping Wang
Luping Wang
YZYingjie Zhao
Yingjie Zhao
YMYao Mu
Yao Mu
LQLei Qiu
Lei Qiu
XYXuezhi Yang
Xuezhi Yang
High succinate concentrations are implicated in rheumatoid arthritis (RA) and other inflammatory diseases through G protein–coupled receptor 91 (GPR91)–mediated signaling. Despite the therapeutic potential of targeting GPR91, conflicting reports on the receptor’s inflammatory roles have hindered treatment development. Here, we report that the effects of succinate on GPR91 signaling are biphasic and concentration dependent. At physiological succinate concentration, membrane-localized GPR91 promotes M2 polarization through G q -mediated activation of phospholipase C and intracellular calcium mobilization. In RA, elevated succinate induces GPR91 internalization and mitochondrial translocation, thereby disrupting G q signaling. Mechanistically, mitochondrial GPR91 recruits G s proteins and, together with intracellular succinate, activates the cyclic adenosine monophosphate (cAMP)–protein kinase A (PKA) pathway. PKA then phosphorylates cytidine/uridine monophosphate kinase 2 at serine-404, stabilizing it to enhance mitochondrial DNA (mtDNA) synthesis. Newly synthesized mtDNA is oxidized (forming ox-mtDNA) and released into the cytosol, activating the cyclic GMP-AMP synthase–stimulator of interferon genes pathway to drive macrophage inflammation. Myeloid-specific GPR91 deletion or inhibition of intracellular succinate accumulation alleviates arthritis in mice. This study reveals that GPR91 reprograms signaling by subcellular relocation, providing a promising therapeutic strategy for autoimmune diseases.